Close

Anti-DPYSL2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-609-YC)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-DPYSL2 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • DPYSL2
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

  • Entrez Gene ID
  • 1808
Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-0059-CN 3F4 Mouse Human IgG3 Human brain homogenate
DMAb-610-YC C4G Mouse Human IgG1 Recombinant human CRMP2
DMAb-611-YC N3E Mouse Human IgG2b Recombinant human CRMP2
DMAb-613-YC 10i33 Mouse Human IgG2b, κ Purified recombinant DHP fusion protein
DMAb-614-YC 33CT11.40.3 Mouse IgG2b A KLH conjugated synthetic peptide between 463-492 amino acids from human DRP-2
DMAb-370-YC 1F11 Mouse Human IgG2a, κ DPYSL2 (NP_001377.1, 470 a.a. ~ 571 a.a) partial recombinant protein with GST tag. The immunogen sequence: PRKPFPDFVY KRIKARSRLA ELRGVPRGLY DGPVCEVSVT PKTVTPASSA KTSPAKQQAP PVRNLHQSGF SLSGAQIDDN IPRRTTQRIV APPGGRANIT SL
DMAb-080-YC Y14C Mouse Human IgG2b
DMAb-042-YC 1B1 Mouse IgG2a, κ A 15 residue synthetic peptide derived from C-terminal domain of human collapsing-response mediator protein Type 2.
DMAb-260-YC M539 Mouse Rat IgG1 Synthetic peptide corresponding to Human CRMP2 (phospho T555). Coupled to carrier protein

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-DPYSL2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-609-YC). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.